Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 7/2010

01-07-2010 | Original Article

JC Virus T-Antigen DNA in Gastrointestinal Mucosa of Immunosuppressed Patients: A Prospective, Controlled Study

Authors: Doron Boltin, Alex Vilkin, Zohar Levi, Ori Elkayam, Yaron Niv

Published in: Digestive Diseases and Sciences | Issue 7/2010

Login to get access

Abstract

Background

JC virus (JCV), a polyoma virus, is the etiological agent of progressive multifocal leukoencephalopathy in immunosuppressed patients. JCV T-Ag has proven oncogenic potential and is expressed in colonic polyps and carcinomas. We proposed that the prevalence of JCV T-Ag DNA is higher in the normal gastrointestinal (GI) mucosa of immunosuppressed patients compared with their immunocompetent counterparts.

Aims

To look for JCV T-Ag DNA in the normal gastrointestinal mucosa of immunosuppressed patients compared with immunocompetent controls.

Methods

Macroscopically normal samples of upper and lower GI mucosa were obtained from 38 immunosuppressed patients. A control group included samples from 19 immunocompetent inflammatory bowel disease (IBD) and 29 non-IBD cases. DNA was extracted and polymerase chain reaction (PCR) was performed using primers specific for T-Ag.

Results

JCV T-Ag DNA was found in nine of the immunosuppressed patients (23.7%) and in three of the controls (6.3%; P = 0.02). Transplant recipients had a particularly high prevalence of JCV T-Ag DNA (35.3%). Patients with IBD receiving immunosuppressive drugs had a higher prevalence of JCV T-Ag DNA in comparison with IBD patients who did not receive immunosuppression (22.2% versus 10.5%, respectively), but this difference was not statistically significant (P = 0.574).

Conclusion

JCV T-Ag DNA is more prevalent in the upper and lower GI mucosa of immunosuppressed patients, possibly indicating that the virus resides in these patients. This may account for the higher prevalence of GI carcinomas in immunosuppressed patients.
Literature
1.
Tibbles LA. Reducing the risk of viral infection in renal transplantation. Transplant Proc. 2008;40(10 Suppl):S48–S51.CrossRefPubMed
2.
Morrison VA, Rai KR, Peterson BL. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup study cancer and leukemia group B 9011. J Clin Oncol. 2001;19:3611–3621.PubMed
3.
White MK, Khalili K. Polyomaviruses and human cancer: Molecular mechanisms underlying patterns of tumorigenesis. Virology. 2004;324:1–16.CrossRefPubMed
4.
Raj GV, Gallia GL, Chang CF, Khalili K. T-antigen-dependent transcriptional initiation and its role in the regulation of human neurotropic JC virus late gene expression. J Gen Virol. 1998;79:2147–2155.PubMed
5.
Kitamura T, Kunitake T, Guo J, et al. Transmission of the human polyomavirus JC virus occurs both within the family and outside the family. J Clin Microbiol. 1994;32:2359–2363.PubMed
6.
Rossi A, Delbue S, Mazziotti R, et al. Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects. J Med Virol. 2007;79:408–412.CrossRefPubMed
7.
Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: Implications for viral latency. J Virol. 1996;70:7004–7012.PubMed
8.
Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy. J Infect Dis. 2002;186(Suppl 2):S180–S186.CrossRefPubMed
9.
Delbue S, Branchetti E, Boldorini R, et al. Presence and expression of JCV early gene large T Antigen in the brains of immunocompromised and immunocompetent individuals. J Med Virol. 2008;80:2147–2152.CrossRefPubMed
10.
Elsner C, Dorries K. Evidence of human polyomavirus BK and JC infection in normal brain tissue. Virology. 1992;191:72–80.CrossRefPubMed
11.
Dorries K. Progressive multifocal leucoencephalopathy: Analysis of JC virus DNA from brain and kidney tissue. Virus Res. 1984;1:25–38.CrossRefPubMed
12.
Caldarelli-Stefano R, Vago L, Omodeo-Zorini E, et al. Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals. J Neurovirol. 1999;5:125–133.CrossRefPubMed
13.
Monaco MC, Jensen PN, Hou J. Detection of JC virus DNA in human tonsil tissue: Evidence for site of initial viral infection. J Virol. 1998;72:9918–9923.PubMed
14.
Astrom KE, Mancall EL, Richardson EP. Progressive multifocal leukoencephalopathy: A hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain. 1958;81:93–111.CrossRefPubMed
15.
Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int. 2005;17:658–665.CrossRefPubMed
16.
Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun. 2008;30:90–98.CrossRefPubMed
17.
Kleinschmidt-DeMasters BK, Tyler KL. Progressive Multifocal leucoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369–374.CrossRefPubMed
18.
Langer-Gould A, Atlas SW, Bollen AW, Pelletier D. Progressive Multifocal Leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;35:375–381.CrossRef
19.
Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353:362–368.CrossRefPubMed
20.
Ferrante P, Caldarelli-Stefano R, Omodeo-Zorini E. Comprehensive investigation of the presence of JC virus in AIDS patients with and without progressive multifocal leukoencephalopathy. J Med Virol. 1997;52:235–242.CrossRefPubMed
21.
Ricciardiello L, Laghi L, Ramamirtham P. JC virus DNA sequences are frequently present in the human upper and lower gastrointestinal tract. Gastroenterology. 2000;119:1228–1235.CrossRefPubMed
22.
Jung WT, Li MS, Goel A, Boland CR. JC virus T-antigen expression in sporadic adenomatous polyps of the colon. Cancer. 2008;112:1028–1036.CrossRefPubMed
23.
Selgrad M, Koornstra JJ, Fini L, et al. JC virus infection in colorectal neoplasia that develops after liver transplantation. Clin Cancer Res. 2008;14:6717–6721.CrossRefPubMed
24.
Niv Y, Goel A, Boland CR. JC virus and colorectal cancer: a possible trigger in the chromosomal instability pathways. Curr Opin Gastroenterol. 2005;21:85–89.PubMed
25.
Enam S, Del Valle L, Lara C, et al. Association of human polyomavirus JCV with colon cancer: Evidence for interaction of viral T-antigen and beta-catenin. Cancer Res. 2002;62:7093–7101.PubMed
26.
Laghi L, Randolph AE, Chauhan DP, et al. JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc Natl Acad Sci USA. 1999;96:7484–7489.CrossRefPubMed
27.
Ricciardiello L, Baglioni M, Giovannini C. Induction of chromosomal instability in colonic cells by the human polyomavirus JC virus. Cancer Res. 2003;63:7256–7262.PubMed
28.
Nosho K, Shima K, Kure S, et al. JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. Neoplasia. 2009;11:87–95.PubMed
29.
Goel A, Li MS, Nagasaka T. Association of JC virus T-antigen expression with the methylator phenotype in sporadic colorectal cancers. Gastroenterology. 2006;130:1950–1961.CrossRefPubMed
30.
Vanchiere JA, Abudayyeh S, Copeland CM, Lu LB, Graham DY, Butel JS. Polyomavirus shedding in the stool of healthy adults. J Clin Microbiol. 2009;47:2388–2391.CrossRefPubMed
31.
Boland CR, Bigler J, Newcomb PA, Lampe JW, Potter JD. Evidence for an association between JC virus and colorectal neoplasia. Cancer Epidemiol Biomarkers Prev. 2004;13:2285–2286.PubMed
32.
Newcomb PA, Bush AC, Stoner GL, Lampe JW, Potter JD, Bigler J. No evidence of an association of JC virus and colon neoplasia. Cancer Epidemiol Biomarkers Prev. 2004;13:662–666.PubMed
33.
Ricciardiello L, Chang DK, Laghi L, Goel A, Chang CL, Boland CR. Mad-1 is the exclusive JC virus strain present in the human colon, and its transcriptional control region has a deleted 98-base-pair sequence in colon cancer tissues. J Virol. 2001;75:1996–2001.CrossRefPubMed
34.
Sanchez W, Talwalkar JA, Gores GJ. Will all liver transplantation patients eventually die from cancer? J Hepatol. 2006;44:13–38.CrossRefPubMed
35.
Amital A, Shitrit D, Raviv Y. Development of malignancy following lung transplantation. Transplantation. 2006;81:547–551.CrossRefPubMed
36.
Nagele H, Bahlo M, Klapdor R, Rodiger W, et al. Tumor marker determination after orthotopic heart transplantation. J Heart Lung Transplant. 1999;18:957–962.CrossRefPubMed
37.
Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905–913.CrossRefPubMed
38.
Rodriguez-Larrain JM, Ziebert JJ, Kfoury AG, Kuwada S, Taylor DO, Renlund DG. Incidence of adenomatous colorectal polyps in cardiac transplant recipients. Transplantation. 1997;64:528–530.CrossRefPubMed
39.
Stewart T, Henderson R, Grayson H, Opelz G. Reduced incidence of rectal cancer compared to gastric and colonic cancer, in a population of 73, 076 men and women chronically immunosuppressed. Clin Cancer Res. 1997;3:51–55.PubMed
40.
Haagsma EB, Hagens VE, Schaapveld M. Increased cancer risk after liver transplantation: A population-based study. J Hepatol. 2001;34:84–91.CrossRefPubMed
41.
Koornstra JJ, Wesseling J, de Jong AE, Vasen HF, Kleibeuker JH, Haagsma EB. Increased risk of colorectal neoplasia in asymptomatic liver transplant recipients. Gut. 2007;56:892–893.CrossRefPubMed
42.
Levitsky J, Miller J, Wang E, et al. Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. Hum Immunol. 2009;70:146–150.CrossRefPubMed
43.
Hodge G, Hodge S, Reynolds P, Holmes M. Intracellular cytokines in blood T cells in lung transplant patients—a more relevant indicator of immunosuppression than drug levels. Clin Exp Immunol. 2005;139:159–164.CrossRefPubMed
Metadata
Title
JC Virus T-Antigen DNA in Gastrointestinal Mucosa of Immunosuppressed Patients: A Prospective, Controlled Study
Authors
Doron Boltin
Alex Vilkin
Zohar Levi
Ori Elkayam
Yaron Niv
Publication date
01-07-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-0986-y

Other articles of this Issue 7/2010

Digestive Diseases and Sciences 7/2010 Go to the issue

Original Article

Intestinal Ischemic Preconditioning After Ischemia/Reperfusion Injury in Rat Intestine: Profiling Global Gene Expression Patterns

Original Article

Effect of Helicobacter bilis Infection on Human Bile Duct Cancer Cells

Original Article

Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment

Original Article

Expression of VEGF, EGFR, and IL-6 in Gastric Adenomas and Adenocarcinomas by Endoscopic Submucosal Dissection

Original Article

Vitamin D Receptor Gene ApaI Polymorphism Is Associated with Susceptibility to Colorectal Cancer

Original Article

Diabetes Mellitus Increases the Risk of Mortality Following Liver Transplantation Independent of MELD Score
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits